Pantojohn IV 40mg Injection

Pantojohn IV 40mg Injection contains Pantoprazole 40mg, a proton pump inhibitor used to reduce stomach acid production for treating various acid-related conditions.

Benefits

This injection offers a rapid onset of action and extended acid suppression, effectively alleviating symptoms such as heartburn and acid reflux. It promotes the healing of tissues damaged by excessive acid. Intravenous administration ensures consistent bioavailability, making it suitable for patients with severe gastric conditions or those unable to take oral medication.

Uses and Indications

• Gastroesophageal Reflux Disease (GERD) and erosive esophagitis.
• Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
• Gastric and duodenal ulcers.
• Prevention of stress-related mucosal damage and upper gastrointestinal bleeding in high-risk hospitalised patients.

The Pantojohn IV 40mg Injection contains:

• Pantoprazole 40 mg (as pantoprazole sodium sesquihydrate), active ingredient.
• Excipients: Sodium citrate, mannitol (E 421), sodium hydroxide.

Dosage and Administration

1. Pantojohn IV 40mg Injection is administered intravenously by a qualified healthcare professional in a clinical setting.
2. For GERD and erosive esophagitis, the recommended adult dosage is 40 mg once daily. This can be given as an intravenous injection over at least 2 minutes or as an intravenous infusion over 15 minutes, typically for up to 7 to 10 days.
3. For pathological hypersecretory conditions, including Zollinger-Ellison Syndrome, the initial adult dosage is 80 mg every 12 hours, administered by intravenous injection over at least 2 minutes or infusion over 15 minutes. Dosing frequency may be adjusted based on individual acid output measurements.
4. Switch to an appropriate oral medication as soon as the patient is able to tolerate oral treatment.
5. To prepare, reconstitute each 40 mg vial with 10 mL of 0.9% Sodium Chloride Injection. For infusion, the reconstituted solution can be further diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection.

Storage and Disposal

• Store unreconstituted vials at 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). Protect from light.
• The reconstituted solution may be stored for up to 6 hours at room temperature (up to 30°C) prior to further dilution.
• Diluted solutions must be used within 24 hours from the time of initial reconstitution. Do not freeze the reconstituted or diluted solution.
• Discard any unused portion of the medicine.
• Dispose of medicines responsibly; do not throw them away via wastewater or household waste.

Precautions and Safety

• Pantojohn IV 40mg Injection is contraindicated in patients with known hypersensitivity reactions to pantoprazole, any substituted benzimidazoles, or any component of the formulation.
• It is also contraindicated in patients receiving rilpivirine-containing products.
• Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy. Further investigation should be considered if symptoms persist despite adequate treatment.
• Prolonged use (over one year) or high doses of proton pump inhibitors may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine, particularly in older adults.
• Long-term use may lead to low magnesium levels (hypomagnesemia). Symptoms can include fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, and increased heart rate. Regular blood tests may be necessary to monitor magnesium levels.
• Acute interstitial nephritis, severe cutaneous adverse reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis), and Clostridioides difficile-associated diarrhea have been reported with PPI use.
• Caution is advised for patients with severe liver problems; liver enzymes should be monitored during therapy.
• Injection site reactions, including thrombophlebitis, can occur. The infusion site should be monitored regularly.
• Pantoprazole may interfere with certain laboratory investigations, such as urine screening for tetrahydrocannabinol (THC) and diagnostics for neuroendocrine tumours.
• Zinc supplementation may be considered for patients predisposed to zinc deficiency, as the formulation may contain edetate disodium (EDTA).

Side Effects and Risks

• Common side effects include headache, diarrhoea, nausea, abdominal pain, vomiting, flatulence, dizziness, joint pain, and pain, redness, or swelling at the injection site.
• Serious side effects requiring immediate medical attention include blistering, peeling, or bleeding skin; sores on the lips, nose, mouth, or genitals; swollen glands; shortness of breath; fever; flu-like symptoms; rash; hives; itching; swelling of the eyes, face, lips, mouth, throat, or tongue; difficulty breathing or swallowing; hoarseness; irregular, fast, or pounding heartbeat; muscle spasms; uncontrollable shaking; excessive tiredness; lightheadedness; seizures; severe watery diarrhoea with stomach pain or fever; new or worsening joint pain; rash on cheeks or arms sensitive to sunlight; abdominal pain or soreness; blood in stool; increased or decreased urination; blood in urine; fatigue; loss of appetite; and kidney injury.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.